1. Simoens S. Biosimilar medicines and cost-effectiveness. Clinicoecon Outcomes Res. 2011;3:29–36.
2. US Government. Biologics Price Competition and Innovation Act (BPCI Act). 2009. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ . Accessed 4 Aug 2016.
3. US Government. Patient Protection and Affordable Care Act (Affordable Care Act)—amendment of section 351 of the Public Health Service Act. 2010 (last update: 28 Jun 2012). http://www.hhs.gov/healthcare/about-the-law/read-the-law/ . Accessed 4 Aug 2016.
4. World Health Organisation, Expert Committee on Biological Standardization. Guidelines on evaluation of similar biotherapeutic products (SBPs). 2009 (last update: 19 to 23 Oct 2009). http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf . Accessed 3 Nov 2016.
5. US Food and Drugs Administration. Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry. 2015. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf . Accessed 4 Aug 2016.